Mirae Asset Global Investments Co. Ltd. Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mirae Asset Global Investments Co. Ltd. raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,180 shares of the biotechnology company’s stock after purchasing an additional 7,220 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.06% of BioCryst Pharmaceuticals worth $732,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Braidwell LP raised its holdings in shares of BioCryst Pharmaceuticals by 92.1% in the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock worth $37,970,000 after purchasing an additional 2,571,100 shares during the period. Vanguard Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company’s stock worth $108,978,000 after purchasing an additional 302,270 shares during the period. Jump Financial LLC raised its holdings in shares of BioCryst Pharmaceuticals by 371.5% during the 3rd quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company’s stock valued at $2,867,000 after buying an additional 319,037 shares during the period. Deerfield Management Company L.P. Series C raised its holdings in shares of BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after buying an additional 1,964,000 shares during the period. Finally, Rice Hall James & Associates LLC raised its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company’s stock valued at $16,112,000 after buying an additional 402,674 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $4.21 on Thursday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.18 and a one year high of $9.06. The stock’s fifty day moving average is $5.16 and its 200-day moving average is $5.56. The company has a market capitalization of $867.89 million, a PE ratio of -3.57 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.68 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.83.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.